ADLYXIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for ADLYXIN (ADLYXIN).
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
| Metabolism | Metabolized by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase; not extensively metabolized by CYP450. |
| Excretion | Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides). |
| Half-life | Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen. |
| Protein binding | Approximately 55–65% bound to plasma proteins (albumin and α1-acid glycoprotein). |
| Volume of Distribution | Volume of distribution at steady state is approximately 0.5–1.0 L/kg, indicating distribution into total body water with limited tissue penetration. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 100% due to high absorption from injection site and minimal first-pass metabolism; oral bioavailability is negligible due to rapid proteolytic degradation. |
| Onset of Action | Subcutaneous: Onset of glucagon-like peptide-1 (GLP-1) receptor activation occurs within 1–2 hours, with peak effect on gastric emptying and glucose-dependent insulin secretion observed at 2–3 hours. |
| Duration of Action | Duration of antidiabetic effect is approximately 8–12 hours, consistent with twice-daily dosing before meals to optimize postprandial glucose control. |
| Molecular Weight | 4858.5 |
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-50 mL/min: No dose adjustment. GFR <30 mL/min: Not recommended. End-stage renal disease: Contraindicated. |
| Liver impairment | Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Not studied; use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No specific dose adjustment; monitor renal function and volume status due to increased risk of dehydration and renal impairment. |
| 1st trimester | Lixisenatide is contraindicated in pregnancy. Animal studies have shown fetal harm; no adequate human data. |
| 2nd trimester | Lixisenatide is contraindicated in pregnancy. No human data; based on animal studies, risk cannot be excluded. |
| 3rd trimester | Lixisenatide is contraindicated in pregnancy due to potential fetal harm; use insulin if needed. |
Clinical note
Comprehensive clinical and safety monograph for ADLYXIN (ADLYXIN).
| Placental transfer | Low molecular weight (4858.5 Da) suggests potential for placental transfer; animal studies confirm transfer. |
| Breastfeeding | Not recommended during breastfeeding. Lixisenatide is not systemically absorbed to a significant extent, but no human data on excretion in milk; potential for gastrointestinal effects in the infant. |
| Lactation Rating | L4 |
| Teratogenic Risk | ADLYXIN (lixisenatide) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but there are no adequate and well-controlled studies in pregnant women. Due to the physiological changes of pregnancy, including increased blood volume and renal clearance, the drug's effect may be altered. However, based on available data, the risk of major birth defects is not significantly increased compared to the general population. Nevertheless, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
| Fetal Monitoring | Monitor maternal blood glucose levels regularly. Assess for signs of hypoglycemia, especially in the first trimester when insulin sensitivity may be altered. Monitor fetal growth and well-being via ultrasound and fetal heart rate monitoring as clinically indicated. No specific ADLYXIN-related monitoring is required beyond standard prenatal care. |
| Fertility Effects | Animal studies have shown no adverse effects on fertility. However, in clinical trials, no specific human fertility studies have been conducted. The impact on human fertility is unknown but based on the mechanism of action (GLP-1 receptor agonist), it is unlikely to have a direct effect on fertility. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
History of hypersensitivity to lixisenatidePersonal or family history of medullary thyroid carcinoma (MTC)Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Severe gastrointestinal disease (e.g., gastroparesis)End-stage renal disease (eGFR <15 mL/min/1.73 m2)
| Precautions | Risk of thyroid C-cell tumors (medullary thyroid carcinoma), acute pancreatitis, hypoglycemia when used with insulin secretagogues or insulin, renal impairment, gastrointestinal adverse effects, and hypersensitivity reactions. |
| Food/Dietary | Take once daily within 1 hour before the first meal of the day. Avoid high-fat meals as they may delay gastric emptying and exacerbate GI side effects. No specific food restrictions beyond general diabetes management. Separate oral medications that require rapid absorption (e.g., antibiotics, levothyroxine) by at least 1 hour before or 4 hours after lixisenatide dose. |
| Clinical Pearls | ADLYXIN (lixisenatide) is a GLP-1 receptor agonist for type 2 diabetes. Administer within 1 hour before the first meal of the day; skip dose if meal is skipped. Do not mix with insulin in same syringe. Contraindicated in patients with history of pancreatitis or severe GI disease. Monitor for acute kidney injury, especially if on concomitant ACEi/ARBs or diuretics. Delays gastric emptying; caution with oral medications requiring rapid absorption. |
| Patient Advice | Inject once daily within 1 hour before your first meal of the day; if you skip that meal, skip the dose. · Store unused pens in the refrigerator (36°F to 46°F); after first use, can store at room temperature for up to 14 days. · Rotate injection sites (abdomen, thigh, upper arm) to reduce bruising or lipodystrophy. · Avoid use if you have severe stomach problems such as gastroparesis or inflammatory bowel disease. · Seek immediate medical attention if you experience severe abdominal pain with nausea/vomiting (possible pancreatitis). · Report symptoms of gallbladder disease (right upper quadrant pain, fever, jaundice). · Do not take if you have a personal or family history of medullary thyroid carcinoma (MTC); alert doctor for neck lump. |
Loading safety data…